For patients taking the prolonged-release preparation of co-beneldopa (Madopar® CR), there may be clinical situations when an alternative formulation of co-beneldopa needs to be considered e.g. if swallowing difficulties develop. Co-beneldopa dispersible tablets (Madopar® Dispersible) are the formulation of choice for patients who are no longer able to swallow the prolonged-release capsules.
This Medicines Q&A discusses how to convert from Madopar CR capsules to the dispersible tablets.
Principal Pharmacist Critical Evaluation and UKMi Medicines Q&A Lead, Southampton Medicines Advice Service, University Hospital of Southampton NHS Foundation Trust